Skip to main content

Movers & Shakers: Mar 5, 2009


Marijn Dekkers, the president and CEO of Thermo Fisher Scientific, will see his base salary for 2009 increase 4.5 percent to $1.218 million, according to a document filed with the US Securities and Exchange Commission last week.

His new salary takes effect starting April 1. Last year Dekkers had a base salary of $1.165 million. In addition, Dekkers received a cash bonus of more than $1.8 million in 2008 according to the filing. In 2007, he received a cash bonus of more than $1.9 million.

Marc Caspar, executive vice president and COO of the company, will receive a base salary of $739,000 this year, compared to a 2008 base salary of $700,000. He received a 2008 cash bonus of $823,266, compared to a cash bonus of $ 825,775 in 2007.

The base salary of Peter Wilver, senior vice president and CFO of Thermo Fisher, will increase to $600,000 from $565,000. His cash bonus for 2008 was $547,886. In 2007 he received a cash bonus of $513,065.

Fluorotechnics this week appointed James Walker its new CEO, replacing Duncan Veal who is becoming the firm's chief technology officer. Veal also is stepping down as a director.

Walker had been the firm's COO and CFO since July 2002. Prior to joining Fluorotechnics, he was CFO at the Hotel Dynamics Group.

The changes were made "to coincide with the company's shift to major sales growth," from product development, Fluorotechnics said in a statement. "The change in roles for [Walker] and [Veal]
is both timely and logical," Rick Taylor, chairman of the company said.

Protein Discovery last week announced it has hired Jeffrey Komatz to be its CFO.

Komatz had been corporate controller at RTI Biologics, and vice president and corporate controller at Tutogen Medical. Both companies make medical devices that process human and animal tissues.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.